title: Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer.
abstract: Lung cancer incidence continues to rise and is the number one cause of cancer death in both men and women worldwide with projected 221,130 new cases and 156,940 deaths in the United States in 2011.1 Non-small cell lung cancer (NSCLC) represents more than 85% of the cases with most patients having either locally advanced or metastatic disease at the time of initial diagnosis, and approximately 60%-70% of them have an adenocarcinoma histologic subtype. In the last three years, we have seen several advances in the management of NSCLC, with several factors playing an important role in the treatment decision making process. Maintenance therapy has been added to the algorithm of NSCLC management and Pemetrexed has been studied as single agent or in combination in this setting with recent studies showing safety and improved progression free survival (PFS) and/or overall survival (OS), still the disease for the most part has a dismal outcome. More research work needs to be done to identify which patients truly benefit from these approaches, and to whom we should offer maintenance or switch maintenance vs. close observation.
authors.affiliation: Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, Fl, USA.
authors.forename: Michel
authors.initials: M
authors.lastname: Velez
authors.forename: Belisario A
authors.initials: BA
authors.lastname: Arango
authors.forename: Cesar A
authors.initials: CA
authors.lastname: Perez
authors.forename: Edgardo S
authors.initials: ES
authors.lastname: Santos